2025
Efficacy and Safety of IV Thrombolysis for Acute Ischemic Stroke Patients With Moyamoya Disease
Chen H, Colasurdo M, Khunte M, Malhotra A, Gandhi D. Efficacy and Safety of IV Thrombolysis for Acute Ischemic Stroke Patients With Moyamoya Disease. Neurology 2025, 104: e210243. PMID: 39772663, DOI: 10.1212/wnl.0000000000210243.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeTreated with IV thrombolysisIn-hospital mortalityMoyamoya disease patientsIV thrombolysisMoyamoya diseasePropensity score matchingIntracranial hemorrhageRisk factors of acute ischemic strokeSelf-careIschemic stroke patientsAcute ischemic stroke patientsStroke patientsTreating acute ischemic strokeNationwide Readmissions DatabaseRisk factorsRate of routine dischargeRoutine dischargeEfficacy outcomesAssociated with different ratesProspective studyBypass surgeryRetrospective analysisEstablished treatmentReadmissions Database
2024
Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS
Fanaroff A, Vora A, Wojdyla D, Mehran R, Granger C, Goodman S, Aronson R, Windecker S, Alexander J, Lopes R. Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS. American Heart Journal 2024, 280: 60-69. PMID: 39557109, DOI: 10.1016/j.ahj.2024.11.005.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeTime-to-event analysisAtrial fibrillationCoronary syndromeClinical trialsEffect of antithrombotic therapyVitamin K antagonistsProportion of patientsRobust variance estimationRandomized clinical trialsClinical trial endpointsPercutaneous coronary interventionK antagonistsAntithrombotic therapyPoisson regressionTreatment armsFollow-upIschemic eventsPlaceboRate ratiosAntithrombotic agentsTrial endpointsWarfarinCoronary interventionIntervention methodsIntravenous Thrombolysis in Patients With Cervical Artery Dissection
Shu L, Akpokiere F, Mandel D, Field T, Leon Guerrero C, Henninger N, Muppa J, Affan M, Haq Lodhi O, Heldner M, Antonenko K, Seiffge D, Arnold M, Salehi Omran S, Crandall R, Lester E, López-Mena D, Arauz A, Nehme A, Boulanger M, Touzé E, Sousa J, Sargento-Freitas J, Barata V, Castro-Chaves P, Brito M, Khan M, Mallick D, Rothstein A, Khazaal O, Kaufmann J, Engelter S, Traenka C, Aguiar de Sousa D, Soares M, Rosa S, Zhou L, Gandhi P, Mancini S, Metanis I, Leker R, Pan K, Dantu V, Baumgartner K, Burton T, Von Rennenberg R, Nolte C, Choi R, MacDonald J, Bavarsad Shahripour R, Guo X, Ghannam M, Almajali M, Samaniego E, Rioux B, Zine-Eddine F, Poppe A, Fonseca A, Baptista M, Cruz D, Romoli M, De Marco G, Longoni M, Keser Z, Griffin K, Kuohn L, Frontera J, Amar J, Giles J, Zedde M, Pascarella R, Grisendi I, Nzwalo H, Liebeskind D, Molaie A, Cavalier A, Kam W, Mac Grory B, Al Kasab S, Anadani M, Kicielinski K, Eltatawy A, Chervak L, Chulluncuy Rivas R, Aziz Y, Mistry E, Bakradze E, Tran T, Rodrigo-Gisbert M, Requena M, Saleh Velez F, Garcia J, Muddasani V, de Havenon A, Sanchez S, Vishnu V, Yaddanapudi S, Adams L, Browngoehl A, Ranasinghe T, Dunston R, Lynch Z, Penckofer M, Siegler J, Mayer S, Willey J, Zubair A, Cheng Y, Sharma R, Marto J, Krupka D, Klein P, Nguyen T, Asad S, Sarwat Z, Balabhadra A, Patel S, Secchi T, Martins S, Mantovani G, Kim Y, Krishnaiah B, Elangovan C, Lingam S, Qureshi A, Fridman S, Alvarado A, Khasiyev F, Linares G, Mannino M, Terruso V, Tountopoulou A, Tentolouris-Piperas V, Martinez-Marino M, Carrasco Wall V, Indraswari F, El Jamal S, Liu S, Zhou M, Alvi M, Ali F, Sarvath M, Morsi R, Kass-Hout T, Shi F, Zhang J, Sokhi D, Said J, Mongare N, Simpkins A, Gomez R, Sen S, Ghani M, Elnazeir M, Wangqin R, Xiao H, Kala N, Khan F, Stretz C, Mohammadzadeh N, Goldstein E, Furie K, Yaghi S. Intravenous Thrombolysis in Patients With Cervical Artery Dissection. Neurology 2024, 103: e209843. PMID: 39298709, PMCID: PMC11415265, DOI: 10.1212/wnl.0000000000209843.Peer-Reviewed Original ResearchConceptsAcute ischemic stroke symptomsCervical artery dissectionFunctional independenceIntravenous thrombolysisIschemic stroke symptomsStroke symptomsArtery dissectionIncidence of symptomatic intracranial hemorrhageIschemic strokeSymptomatic intracranial hemorrhageSuspected ischemic strokeClass III evidenceMedian ageSymptomatic ICHIntracranial hemorrhageSecondary analysisGuideline recommendationsICH riskIII evidenceFunctional outcomesPatientsThrombolysisCeADYoung adultsDissectionAdjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke
Adeoye O, Broderick J, Derdeyn C, Grotta J, Barsan W, Bentho O, Berry S, Concha M, Davis I, Demel S, Elm J, Gentile N, Graves T, Hoffman M, Huang J, Ingles J, Janis S, Jasne A, Khatri P, Levine S, Majjhoo A, Panagos P, Pancioli A, Pizzella S, Ranasinghe T, Sabagha N, Sivakumar S, Streib C, Vagal A, Wilson A, Wintermark M, Yoo A, Barreto A. Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke. New England Journal Of Medicine 2024, 391: 810-820. PMID: 39231343, PMCID: PMC11528349, DOI: 10.1056/nejmoa2314779.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnticoagulantsArginineCombined Modality TherapyDrug Therapy, CombinationEptifibatideFemaleFibrinolytic AgentsHumansIncidenceInfusions, IntravenousIntracranial HemorrhagesIschemic StrokeMaleMiddle AgedPeptidesPipecolic AcidsPlatelet Aggregation InhibitorsSingle-Blind MethodSulfonamidesThrombectomyThrombolytic TherapyTreatment OutcomeConceptsSymptomatic intracranial hemorrhageIntravenous argatrobanIntravenous thrombolysisAcute ischemic strokeIntracranial hemorrhageIschemic strokeIncidence of symptomatic intracranial hemorrhageSymptom onsetIschemic stroke treated with intravenous thrombolysisAcute ischemic stroke treated with intravenous thrombolysisStroke treated with intravenous thrombolysisAssociated with increased mortalityRankin Scale scoreInitiation of thrombolysisControlled clinical trialsTreatment of acute ischemic strokePlacebo groupEptifibatide groupEfficacy outcomesArgatroban groupStandard treatmentAdjunctive treatmentPlaceboClinical trialsArgatrobanAntithrombotic Strategies for Patients With Peripheral Artery Disease JACC Scientific Statement
Bonaca M, Barnes G, Bauersachs R, Bessada Y, Conte M, Dua A, Hess C, Serhal M, Mena-Hurtado C, Weitz J, Beckman J. Antithrombotic Strategies for Patients With Peripheral Artery Disease JACC Scientific Statement. Journal Of The American College Of Cardiology 2024, 84: 936-952. PMID: 39197984, DOI: 10.1016/j.jacc.2024.06.027.Peer-Reviewed Original ResearchMeSH KeywordsAnticoagulantsFibrinolytic AgentsHumansPeripheral Arterial DiseasePlatelet Aggregation InhibitorsConceptsPeripheral arterial diseaseAntithrombotic strategiesArtery diseaseResponse to antithrombotic therapyLimb eventsRisk of bleedingCoronary artery diseaseAdverse limb eventsAntithrombotic therapyMultidisciplinary working groupClinical scenariosPatientsAssessment of benefit-riskBenefit-riskAnticoagulationDiseaseScientific statementPatient-centeredBleedingThrombolysis for Wake-Up Stroke Versus Non–Wake-Up Unwitnessed Stroke: EOS Individual Patient Data Meta-Analysis
Kamogawa N, Miwa K, Toyoda K, Jensen M, Inoue M, Yoshimura S, Fukuda-Doi M, Kitazono T, Boutitie F, Ma H, Ringleb P, Wu O, Schwamm L, Warach S, Hacke W, Davis S, Donnan G, Gerloff C, Thomalla G, Koga M, Cheng B, Bendszus M, Bladin C, Churilov L, Campbell B, Parsons M, Yassi N, Ebinger M, Endres M, Fiebach J, Kleinig T, Latour L, Lemmens R, Levi C, Leys D, Molina C, Muir K, Nighoghossian N, Pedraza S, Schellinger P, Schwab S, Simonsen C, Song S, Thijs V, Toni D, Hsu C, Wahlgren N. Thrombolysis for Wake-Up Stroke Versus Non–Wake-Up Unwitnessed Stroke: EOS Individual Patient Data Meta-Analysis. Stroke 2024, 55: 895-904. PMID: 38456303, PMCID: PMC10978262, DOI: 10.1161/strokeaha.123.043358.Peer-Reviewed Original ResearchConceptsSymptomatic intracranial hemorrhageIntracranial hemorrhageIntravenous thrombolysisFavorable outcomeUnwitnessed strokeNon-WUSFrequency of favorable outcomesIndividual patient-data meta-analysisMultivariate logistic regression analysisModified Rankin Scale scoreSafety of intravenous thrombolysisRankin Scale scoreEffect of intravenous thrombolysisIntravenous thrombolysis groupLogistic regression analysisUnknown-onset strokeRandomized controlled trialsNo significant differencePatient-level dataData meta-analysisStandard treatmentInsufficient statistical powerPatientsSafety outcomesControlled trialsTenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection
Albers G, Jumaa M, Purdon B, Zaidi S, Streib C, Shuaib A, Sangha N, Kim M, Froehler M, Schwartz N, Clark W, Kircher C, Yang M, Massaro L, Lu X, Rippon G, Broderick J, Butcher K, Lansberg M, Liebeskind D, Nouh A, Schwamm L, Campbell B. Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection. New England Journal Of Medicine 2024, 390: 701-711. PMID: 38329148, DOI: 10.1056/nejmoa2310392.Peer-Reviewed Original ResearchConceptsModified Rankin ScaleSymptomatic intracranial hemorrhageInternal carotid arteryMiddle cerebral arteryRankin ScalePlacebo groupTenecteplase groupIntracranial hemorrhageIncidence of symptomatic intracranial hemorrhageCerebral arteryIncidence of symptomatic intracerebral hemorrhageCarotid arteryPlacebo-controlled trialSymptomatic intracerebral hemorrhageEvidence of occlusionSafety populationDouble-blindPerfusion-imagingMedian timeClinical outcomesIntracerebral hemorrhagePlaceboPerfusion imagingPrimary outcomeOdds ratio
2023
Antithrombotic and Statin Prescription After Intracerebral Hemorrhage in the Get With The Guidelines-Stroke Registry
Murthy S, Zhang C, Shah S, Schwamm L, Fonarow G, Smith E, Bhatt D, Ziai W, Kamel H, Sheth K. Antithrombotic and Statin Prescription After Intracerebral Hemorrhage in the Get With The Guidelines-Stroke Registry. Stroke 2023, 54: 2972-2980. PMID: 37942641, PMCID: PMC10842167, DOI: 10.1161/strokeaha.123.043194.Peer-Reviewed Original ResearchConceptsIschemic vascular diseaseProportion of patientsGuidelines-Stroke registryLipid-lowering therapyIntracerebral hemorrhageVascular diseaseStatin therapyAnticoagulation therapyCardiovascular eventsAtrial fibrillationFuture major cardiovascular eventsLower admission National InstitutesPrevious lipid-lowering therapyAdmission National InstitutesFavorable discharge outcomeIschemic cardiovascular eventsHealth Stroke ScaleMajor cardiovascular eventsLipid-lowering medicationsCross-sectional studyMultiple logistic regressionLogistic regression analysisAntiplatelet medicationsAntiplatelet therapyStatin medicationThe Search for Optimal Antithrombotic Therapy With LAAO Are We There Yet? ∗
Sherwood M, Vora A. The Search for Optimal Antithrombotic Therapy With LAAO Are We There Yet? ∗. JACC Cardiovascular Interventions 2023, 16: 2719-2721. PMID: 37943197, DOI: 10.1016/j.jcin.2023.09.019.Peer-Reviewed Original ResearchTrends in Use of Intravenous Thrombolysis and Endovascular Thrombectomy in Patients With Acute Stroke With Large Vessel Occlusion 2016 to 2020 and Impact of COVID‐19 Pandemic
Khunte M, Chen H, Khunte A, Payabvash S, Gandhi D, Malhotra A. Trends in Use of Intravenous Thrombolysis and Endovascular Thrombectomy in Patients With Acute Stroke With Large Vessel Occlusion 2016 to 2020 and Impact of COVID‐19 Pandemic. Journal Of The American Heart Association 2023, 12: e029579. PMID: 37889182, PMCID: PMC10727381, DOI: 10.1161/jaha.122.029579.Peer-Reviewed Original ResearchIntravenous thrombolysis prior to endovascular thrombectomy in elderly stroke patients: An analysis of the National Inpatient Sample database
Chen H, Khunte M, Colasurdo M, Malhotra A, Gandhi D. Intravenous thrombolysis prior to endovascular thrombectomy in elderly stroke patients: An analysis of the National Inpatient Sample database. Journal Of The Neurological Sciences 2023, 454: 120842. PMID: 37856997, DOI: 10.1016/j.jns.2023.120842.Peer-Reviewed Original ResearchConceptsNational Inpatient Sample databaseHospital mortalityHemorrhagic complicationsIntravenous thrombolysisEndovascular thrombectomyEVT patientsIVT treatmentThrombectomy centreElderly patientsMultivariable logistic regression modelSample databaseStroke risk factorsElderly stroke patientsCross-sectional studyLarge-scale cross-sectional studyOutcomes of interestHigh rateLogistic regression modelsPatients 80Medical comorbiditiesOnly patientsPatient demographicsStroke etiologyThrombolytic treatmentHemorrhagic riskSafety Outcomes of Mechanical Thrombectomy Versus Combined Thrombectomy and Intravenous Thrombolysis in Tandem Lesions
Rodriguez-Calienes A, Galecio-Castillo M, Farooqui M, Hassan A, Jumaa M, Divani A, Ribo M, Abraham M, Petersen N, Fifi J, Guerrero W, Malik A, Siegler J, Nguyen T, Yoo A, Linares G, Janjua N, Quispe-Orozco D, Tekle W, Alhajala H, Ikram A, Rizzo F, Qureshi A, Begunova L, Matsoukas S, Vigilante N, Salazar-Marioni S, Abdalkader M, Gordon W, Soomro J, Turabova C, Vivanco-Suarez J, Mokin M, Yavagal D, Jovin T, Sheth S, Ortega-Gutierrez S. Safety Outcomes of Mechanical Thrombectomy Versus Combined Thrombectomy and Intravenous Thrombolysis in Tandem Lesions. Stroke 2023, 54: 2522-2533. PMID: 37602387, PMCID: PMC10599264, DOI: 10.1161/strokeaha.123.042966.Peer-Reviewed Original ResearchConceptsRisk of sICHParenchymal hematoma type 2Symptomatic intracranial hemorrhageRankin Scale score 0Intravenous antiplatelet therapyIntravenous thrombolysisFavorable functional outcomeMechanical thrombectomyHemorrhagic transformationFunctional outcomeType 2Antiplatelet therapyHospital mortalitySuccessful reperfusionComplete reperfusionScore 0Tandem lesionsAnterior circulation tandem lesionsExcellent functional outcomeIVT treatmentStroke centersMulticenter cohortPrimary outcomeRevascularization techniquesAlone groupRecent Vitamin K Antagonist Use and Intracranial Hemorrhage After Endovascular Thrombectomy for Acute Ischemic Stroke
Mac Grory B, Holmes D, Matsouaka R, Shah S, Chang C, Rison R, Jindal J, Holmstedt C, Logan W, Corral C, Mackey J, Gee J, Bonovich D, Walker J, Gropen T, Benesch C, Dissin J, Pandey H, Wang D, Unverdorben M, Hernandez A, Reeves M, Smith E, Schwamm L, Bhatt D, Saver J, Fonarow G, Peterson E, Xian Y. Recent Vitamin K Antagonist Use and Intracranial Hemorrhage After Endovascular Thrombectomy for Acute Ischemic Stroke. JAMA 2023, 329: 2038-2049. PMID: 37338878, PMCID: PMC10282891, DOI: 10.1001/jama.2023.8073.Peer-Reviewed Original ResearchConceptsRisk of sICHSymptomatic intracranial hemorrhageVitamin K antagonistsAcute ischemic strokeSecondary end pointsEndovascular thrombectomyVKA useIschemic strokeHospital mortalityEnd pointIntracranial hemorrhageOral vitamin K antagonistsVitamin K antagonist useGuidelines-Stroke programPrior VKA usePrimary end pointObservational cohort studyLarge vessel occlusionRisk of complicationsAmerican Heart AssociationUse of anticoagulantsSignificant differencesHospital presentationSICH riskAntagonist useShorter Door-to-Needle Times Are Associated With Better Outcomes After Intravenous Thrombolytic Therapy and Endovascular Thrombectomy for Acute Ischemic Stroke
Man S, Solomon N, Mac Grory B, Alhanti B, Uchino K, Saver J, Smith E, Xian Y, Bhatt D, Schwamm L, Hussain M, Fonarow G. Shorter Door-to-Needle Times Are Associated With Better Outcomes After Intravenous Thrombolytic Therapy and Endovascular Thrombectomy for Acute Ischemic Stroke. Circulation 2023, 148: 20-34. PMID: 37199147, PMCID: PMC10356148, DOI: 10.1161/circulationaha.123.064053.Peer-Reviewed Original ResearchConceptsIntravenous thrombolytic therapyAcute ischemic strokeGood long-term functional outcomeLong-term functional outcomeShorter DTN timesEndovascular thrombectomyFunctional outcomeDTN timeIschemic strokeCause mortalityNeedle timeThrombolytic therapyCox proportional hazards modelModified Rankin Scale (mRS) 0Older US patientsRankin Scale 0Multivariate logistic regressionProportional hazards modelLongitudinal functional outcomesHome timeEligible patientsEVT candidatesEVT timesGuidelines-StrokeThrombolytic administrationEffect of intravenous thrombolysis before endovascular therapy on outcomes in patients with large core infarct
Anadani M, Almallouhi E, Maier I, Al Kasab S, Jabbour P, Kim J, Wolfe S, Rai A, Starke R, Psychogios M, Samaniego E, Arthur A, Yoshimura S, Cuellar H, Howard B, Alawieh A, Fragata I, Polifka A, Mascitelli J, Osbun J, Matouk C, Park M, Levitt M, Dumont T, Williamson R, Spiotta A. Effect of intravenous thrombolysis before endovascular therapy on outcomes in patients with large core infarct. Journal Of NeuroInterventional Surgery 2023, 15: jnis-2022-019537. PMID: 36990690, DOI: 10.1136/jnis-2022-019537.Peer-Reviewed Original ResearchConceptsAlberta Stroke Program Early CT ScorePropensity score matching analysisEfficacy of bridging therapyScore matching analysisTreated with MTIntravenous thrombolysisIntracerebral hemorrhageCore infarctBridging therapyMatched cohortMechanical thrombectomyIncreased risk of hemorrhageRisk of hemorrhageMatching analysisEffect of intravenous thrombolysisCT scoreBaseline characteristicsEndovascular therapyFavorable outcomeRetrospective analysisCompare outcomesIncreased riskPatientsSafety outcomesAneurysm RegistryComplications of Intravenous Tenecteplase Versus Alteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis
Rose D, Cavalier A, Kam W, Cantrell S, Lusk J, Schrag M, Yaghi S, Stretz C, de Havenon A, Saldanha I, Wu T, Ranta A, Barber P, Marriott E, Feng W, Kosinski A, Laskowitz D, Poli S, Mac Grory B. Complications of Intravenous Tenecteplase Versus Alteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. Stroke 2023, 54: 1192-1204. PMID: 36951049, PMCID: PMC10133185, DOI: 10.1161/strokeaha.122.042335.Peer-Reviewed Original ResearchConceptsSymptomatic intracranial hemorrhageAcute ischemic strokeIntracranial hemorrhageIschemic strokeSystematic reviewIntravenous tenecteplaseRelative riskHigh-dose groupRisk of complicationsPrior systematic reviewsTenecteplase-treated patientsFull-text articlesWeb of ScienceGastrointestinal hemorrhageAdult patientsExtracranial hemorrhageNoncomparative studySecondary outcomesPooled riskPrimary outcomeTreatment complicationsAbsolute riskCochrane LibraryInterventional studyMedium doseAssessing the safety of continued perioperative antithrombotic therapy in endoscopic airway surgery for laryngotracheal stenosis
Shah H, Reeder A, Rohrbaugh T, Kohli N. Assessing the safety of continued perioperative antithrombotic therapy in endoscopic airway surgery for laryngotracheal stenosis. American Journal Of Otolaryngology 2023, 44: 103857. PMID: 37030129, PMCID: PMC10033492, DOI: 10.1016/j.amjoto.2023.103857.Peer-Reviewed Original ResearchConceptsEndoscopic airway surgeryAntithrombotic therapyAirway surgeryPerioperative continuationLaryngotracheal stenosisEndoscopic surgeryOpen airway surgeryPerioperative antithrombotic therapyCases of patientsPerioperative cessationPreoperative continuationPostoperative bleedingProlonged intubationAntithrombotic usePrimary outcomeRetrospective studyTracheal stenosisSingle institutionProspective InvestigationInclusion criteriaSurgeryPatientsTherapyComplicationsStenosisEffect of Alteplase on Ischemic Stroke Mortality Is Dependent on Stroke Severity
de Havenon A, Abbasi M, Yaghi S, Delic A, Bangad A, Johnston K, Tirschwell D, Sheth K. Effect of Alteplase on Ischemic Stroke Mortality Is Dependent on Stroke Severity. Annals Of Neurology 2023, 93: 1106-1116. PMID: 36852919, DOI: 10.1002/ana.26621.Peer-Reviewed Original ResearchConceptsIV-tPAHigher NIHSSIschemic strokeAtrial fibrillationNational Inpatient Sample (NIS) 2016Non-Hispanic white raceOlder ageBaseline National InstitutesDEFUSE-3 trialsHealth Stroke ScalePost-stroke mortalityIschemic stroke mortalityEffect of alteplaseRisk of mortalityLogistic regression modelsAnn NeurolFAST-MAGIMS IIISevere ISHospital mortalityIntravenous alteplaseSevere strokeStroke ScaleStroke severityFunctional outcomeFactor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis
Park D, An S, Arif A, Sana M, Vij A. Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis. BMC Cardiovascular Disorders 2023, 23: 100. PMID: 36814196, PMCID: PMC9945392, DOI: 10.1186/s12872-023-03067-4.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAnticoagulantsFactor Xa InhibitorsFibrinolytic AgentsHemorrhageHumansObesity, MorbidVenous ThromboembolismConceptsClinically relevant non-major bleedingNon-vitamin K antagonist oral anticoagulantsVitamin K antagonistsMorbidly obese patientsRecurrent venous thromboembolismObese patientsVenous thromboembolismFactor Xa inhibitorsK antagonistsXa inhibitorsTreating morbidly obese patientsVitamin K antagonist groupNon-major bleedingMeta-analysisTreat venous thromboembolismMeta-analysis of studiesHigh-risk populationAssociated with lower oddsRandomized controlled trialsOral anticoagulantsGoogle Scholar databasesMorbid obesityNo significant differenceLandmark trialsAtrial fibrillationA Genomic Risk Score Identifies Individuals at High Risk for Intracerebral Hemorrhage
Myserlis E, Georgakis M, Demel S, Sekar P, Chung J, Malik R, Hyacinth H, Comeau M, Falcone G, Langefeld C, Rosand J, Woo D, Anderson C. A Genomic Risk Score Identifies Individuals at High Risk for Intracerebral Hemorrhage. Stroke 2023, 54: 973-982. PMID: 36799223, PMCID: PMC10050100, DOI: 10.1161/strokeaha.122.041701.Peer-Reviewed Original ResearchMeSH KeywordsCerebral HemorrhageFibrinolytic AgentsGenome-Wide Association StudyGenomicsHumansRisk FactorsConceptsClinical risk factorsIncident intracerebral hemorrhageIntracerebral hemorrhageHigh-risk populationRisk factorsGenomic risk scoresRisk scoreHigher oddsHigh riskRisk factor-adjusted modelsStandard clinical risk factorsVascular risk factorsLobar intracerebral hemorrhageLow-risk populationNonlobar intracerebral hemorrhageUse of anticoagulantsPopulation-based UK Biobank cohortUK Biobank cohortEuropean ancestryAntithrombotic treatmentClinical predictorsSD incrementMedication usersLifetime riskMetaGRS
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply